Skip to main content
. Author manuscript; available in PMC: 2020 Mar 3.
Published in final edited form as: ACS Nano. 2019 Oct 11;13(10):11034–11048. doi: 10.1021/acsnano.9b02807

Figure 5.

Figure 5.

(A) Biodistribution of IVM, NT-OH-IVM-NP, and T-Fc-IVM-NP in intestine and blood of Balb/c female mice after 24 h of post administration by oral gavage at a dose of 40 mg/kg with respect to IVM. (B) FcRn expression level in mice intestinal tissue by Western blotting. (C) Cytokine expression in the blood plasma of the IVM or its NP-treated mice. (D) H & E staining of major tissue after treatment with saline or T-Fc-IVM-NP.